$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000143922218000009 Filed on May 04, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$40.41M	$8.762M	$10.51M
YoY Change	256.2%	-16.62%	-66.41%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$40.41M	$8.762M
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$26.63M	$24.55M	$14.82M
YoY Change	65.1%	65.65%	36.72%
% of Gross Profit	65.89%	280.19%
Research & Development	$86.73M	$78.22M	$62.73M
YoY Change	8.66%	24.7%	42.45%
% of Gross Profit	214.6%	892.76%
Depreciation & Amortization	$1.800M	$1.725M	$1.591M
YoY Change	12.5%	8.42%	27.69%
% of Gross Profit	4.45%	19.69%
Operating Expenses	$113.4M	$102.8M	$77.56M
YoY Change	18.15%	32.52%	41.33%
Operating Profit	-$72.95M	-$94.01M	-$67.05M
YoY Change	-13.77%	40.22%	184.17%
Interest Expense	$4.200M	$3.190M	$880.0K
YoY Change	176.32%	262.5%	120.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$68.75M	-$90.83M	-$66.17M
YoY Change	-17.25%	37.27%	185.22%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$68.75M	-$90.83M	-$66.17M
YoY Change	-17.26%	37.27%	185.22%
Net Earnings / Revenue	-170.1%	-1036.58%	-629.67%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.191M	-$1.631M	-$1.565M
COMMON SHARES
Basic Shares Outstanding	57.61M shares	57.33M shares	42.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$716.9M	$782.5M	$479.8M
YoY Change	22.34%	63.09%	53.34%
Cash & Equivalents	$210.3M	$364.5M	$200.3M
Short-Term Investments	$506.6M	$418.0M	$279.5M
Other Short-Term Assets	$15.50M	$15.60M	$12.40M
YoY Change	19.23%	25.81%	34.78%
Inventory
Prepaid Expenses
Receivables	$1.600M	$1.400M
Other Receivables	$19.70M	$3.500M
Total Short-Term Assets	$753.8M	$803.0M	$506.9M
YoY Change	24.66%	58.42%	53.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.13M	$23.73M	$24.14M
YoY Change	-2.57%	-1.69%	5.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$219.7M	$212.3M	$23.40M
YoY Change	69.13%	807.26%	-45.45%
Other Assets	$595.0K	$1.104M	$2.888M
YoY Change	-52.36%	-61.77%	244.63%
Total Long-Term Assets	$244.5M	$237.1M	$50.45M
YoY Change	56.78%	370.04%	-24.3%
TOTAL ASSETS
Total Short-Term Assets	$753.8M	$803.0M	$506.9M
Total Long-Term Assets	$244.5M	$237.1M	$50.45M
Total Assets	$998.2M	$1.040B	$557.3M
YoY Change	31.24%	86.63%	40.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.32M	$17.93M	$16.15M
YoY Change	-26.01%	11.02%	17.5%
Accrued Expenses	$25.79M	$17.01M	$25.11M
YoY Change	-12.98%	-32.29%	105.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$84.87M	$74.70M	$82.43M
YoY Change	-9.37%	-9.38%	82.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$90.20M	$99.80M	$167.5M
YoY Change	-42.91%	-40.42%	795.72%
Total Long-Term Liabilities	$90.20M	$99.80M	$167.5M
YoY Change	-42.91%	-40.42%	795.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.87M	$74.70M	$82.43M
Total Long-Term Liabilities	$90.20M	$99.80M	$167.5M
Total Liabilities	$175.1M	$174.5M	$249.9M
YoY Change	-30.41%	-30.16%	292.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$918.2M	-$758.6M	-$549.6M
YoY Change	45.13%	38.04%	78.5%
Common Stock	$1.744B	$1.718B	$857.1M
YoY Change	52.65%	100.39%	33.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$823.1M	$865.6M	$307.4M
YoY Change
Total Liabilities & Shareholders Equity	$998.2M	$1.040B	$557.3M
YoY Change	31.24%	86.63%	40.69%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$68.75M	-$90.83M	-$66.17M
YoY Change	-17.26%	37.27%	185.22%
Depreciation, Depletion And Amortization	$1.800M	$1.725M	$1.591M
YoY Change	12.5%	8.42%	27.69%
Cash From Operating Activities	-$67.40M	-$99.00M	-$74.07M
YoY Change	14.24%	33.65%	289.86%
INVESTING ACTIVITIES
Capital Expenditures	-$1.400M	$1.432M	$293.0K
YoY Change	40.0%	388.74%	-88.43%
Acquisitions
YoY Change
Other Investing Activities	-$94.90M	-$166.1M	$109.8M
YoY Change	-65.44%	-251.28%	-992.68%
Cash From Investing Activities	-$96.30M	-$167.5M	$109.6M
YoY Change	-65.08%	-252.92%	-840.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$516.2M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.500M	$528.3M	$4.046M
YoY Change	-96.52%	12956.77%	267.82%
NET CHANGE
Cash From Operating Activities	-67.40M	-$99.00M	-$74.07M
Cash From Investing Activities	-96.30M	-$167.5M	$109.6M
Cash From Financing Activities	9.500M	$528.3M	$4.046M
Net Change In Cash	-154.2M	$261.7M	$39.52M
YoY Change	150.32%	562.24%	-220.87%
FREE CASH FLOW
Cash From Operating Activities	-$67.40M	-$99.00M	-$74.07M
Capital Expenditures	-$1.400M	$1.432M	$293.0K
Free Cash Flow	-$66.00M	-$100.4M	-$74.37M
YoY Change	13.79%	35.05%	245.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2017Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2448000	USD
CY2018Q1	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	3512000	USD
CY2017Q1	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	6379000	USD
CY2017Q1	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2018Q1	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	195000	USD
CY2017Q1	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	6000	USD
CY2018Q1	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	1064000	USD
CY2017Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14849000	USD
CY2018Q1	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	9951000	USD
CY2018Q1	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	73000	USD
CY2017Q1	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	329000	USD
CY2018Q1	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	0	USD
CY2017Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1222000	USD
CY2018Q1	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1417000	USD
CY2017Q1	agio	Public Offering Costs In Accounts Payable And Accrued Expenses PublicOfferingCostsInAccountsPayableAndAccruedExpenses	0	USD
CY2018Q1	agio	Public Offering Costs In Accounts Payable And Accrued Expenses PublicOfferingCostsInAccountsPayableAndAccruedExpenses	158000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57605621	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
CY2018Q1	dei	Trading Symbol TradingSymbol	AGIO
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22767000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	17932000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-163000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	406000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17005000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3140000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1853000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1389000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2643000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1174904000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1717609000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10734000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14522000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6262177	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6515743	shares
CY2017Q4	us-gaap	Assets Assets	614397000	USD
CY2018Q1	us-gaap	Assets Assets	1040126000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	445261000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	802993000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1389000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2634000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	466415000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	632912000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	439400000	USD
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	417981000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	465026000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	630278000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	572700000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	321212000	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	143814000	USD
CY2018Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	212297000	USD
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	240	security
CY2018Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	257	security
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	213000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	605000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200278000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364469000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39524000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	261745000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	994700000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48826153	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57541613	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48826153	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57541613	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66065000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92079000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5984000	USD
CY2018Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	323000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	301000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	550000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18155000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18002000	USD
CY2018Q1	us-gaap	Deferred Revenue DeferredRevenue	124184000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37842000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	39212000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125798000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	81831000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	1591000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	1725000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15693000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4966000	USD
CY2017Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14823000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24550000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	24000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-994000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4469000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6889000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-17144000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	801000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-96000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1924000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3141000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3425000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1901000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	881000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3187000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	238894000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	174532000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	614397000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1040126000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94941000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	74699000	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10508000	USD
CY2018Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7345000	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2018Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4046000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	528277000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	109552000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-167532000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74074000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-99000000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-66166000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-90825000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	77555000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	102774000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-67047000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-94012000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	349000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	235000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	101000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	891000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1104000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1254000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	188000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26740000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	330971000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	293000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1432000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17655000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15614000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516200000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516206000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4146000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12259000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	136585000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	164871000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24431000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23732000	USD
CY2017Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2018Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2776000	USD
CY2018Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62732000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78224000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798061000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-849430000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-758605000	USD
CY2017Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	10508000	USD
CY2018Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	7345000	USD
CY2017Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
CY2018Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0	USD
CY2018Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	132600000	USD
CY2018Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod	P9M
CY2017Q1	us-gaap	Revenues Revenues	10508000	USD
CY2018Q1	us-gaap	Revenues Revenues	8762000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2018Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1417000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10734000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14522000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2863417	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	48.14
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	102127	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1107220	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5577562	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6104808	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.58
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	56.03
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6104808	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	56.03
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.81
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	88.78
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	77.22
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8152986	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	477847	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	375503000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	865594000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42280525	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55694603	shares
CY2018Q1	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018 we adopted ASC 606 under the modified retrospective method. Prior to January 1, 2018 we accounted for the Collaboration Agreements under ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting under ASC 606</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In adopting ASC 606, </font><font style="font-family:inherit;font-size:10pt;">we applied the practical expedient that permits aggregating the effect of all modifications that occurred prior to January 1, 2018. No other practical expedients were used.</font><font style="font-family:inherit;font-size:10pt;"> Similar to the accounting under ASC 605-25, the 2016 Agreement was determined to be a modification of the 2010 Agreement and the AG-881 Agreements. In determining the appropriate amount of revenue to be recognized under ASC 606, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfy each performance obligation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price, or SSP, for each performance obligation identified in the contract. We use key assumptions to determine the SSP, which include forecast of revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</font></div></div>

Files In Submission

Name	View Source	Status
0001439222-18-000009-index-headers.html	Edgar Link	pending
0001439222-18-000009-index.html	Edgar Link	pending
0001439222-18-000009.txt	Edgar Link	pending
0001439222-18-000009-xbrl.zip	Edgar Link	pending
agio-033118x10q.htm	Edgar Link	pending
agio-20180331.xml	Edgar Link	completed
agio-20180331.xsd	Edgar Link	pending
agio-20180331_cal.xml	Edgar Link	unprocessable
agio-20180331_def.xml	Edgar Link	unprocessable
agio-20180331_lab.xml	Edgar Link	unprocessable
agio-20180331_pre.xml	Edgar Link	unprocessable
exhibit10-1x03x31x2018.htm	Edgar Link	pending
exhibit31-1x03x31x2018.htm	Edgar Link	pending
exhibit31-2x03x31x2018.htm	Edgar Link	pending
exhibit32-1x03x31x2018.htm	Edgar Link	pending
exhibit32-2x03x31x2018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2018 Q2 Form 10-Q Financial Statement

#000143922218000009 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2018 Q2 Form 10-Q Financial Statement

#000143922218000009 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio